R. Morgan

Oncology · Nature · 2001–2019

A researcher in the Science corpus: 16 papers; trusts 1 researcher and is trusted by 6 researchers here, as inferred from the citation graph.

Subfields

Oncology — 103 citations into it; #404 of 1,698 by trust here, #85 by citations
Immunology — 56 citations into it; #1,896 of 2,160 by trust here, #348 by citations

Whom R. Morgan trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

Who trusts R. Morgan overall

Papers from R. Morgan's perspective

Ordered by how strongly the researchers R. Morgan trusts endorse each paper. Same corpus, a different order for every researcher.

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma (New England Journal of Medicine)
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer (New England Journal of Medicine)
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer (New England Journal of Medicine)
Cancer regression and neurologic toxicity following anti-MAGE-A3 TCR gene therapy (Journal of immunotherapy)
Identification of a Titin-Derived HLA-A1–Presented Peptide as a Cross-Reactive Target for Engineered MAGE A3–Directed T Cells (Science Translational Medicine)
Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma (Nature Medicine)
IL-2: The First Effective Immunotherapy for Human Cancer (Journal of Immunology)
Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. (Blood)
Cancer immunotherapy: moving beyond current vaccines (Nature Medicine)
Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. (Journal of Clinical Oncology)

Their papers

Specific inhibition of gene expression by small double-stranded RNAs in invertebrate and vertebrate systems (2001) — 1,110 citations
Whole genomes redefine the mutational landscape of pancreatic cancer (2015) — 2,461 citations
Genomic analyses identify molecular subtypes of pancreatic cancer (2016) — 3,221 citations
Cancer regression and neurologic toxicity following anti-MAGE-A3 TCR gene therapy (2013) — 1,094 citations
Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. (2011) — 1,605 citations
Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. (2010) — 1,314 citations
Anti‐BCMA CAR T‐Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma (2019) — 1,364 citations
A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T cell receptor: Long term follow up and correlates with response (2014) — 728 citations
Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia. (2013) — 560 citations
Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes (2012) — 1,987 citations
B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. (2012) — 1,404 citations
T Cells Targeting Carcinoembryonic Antigen Can Mediate Regression of Metastatic Colorectal Cancer but Induce Severe Transient Colitis. (2011) — 813 citations
Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. (2010) — 2,497 citations
Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. (2009) — 1,438 citations
Adoptive cell transfer: a clinical path to effective cancer immunotherapy (2008) — 1,698 citations
Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes (2006) — 2,728 citations